logo
Share SHARE
FONT-SIZE Plus   Neg

GE Healthcare Reveals Phase 3 Results For Imaging Agent Flutemetamol

GE Healthcare, a unit of diversified conglomerate General Electric Co. (GE: Quote), Wednesday released results from four pooled brain biopsy studies and results from a brain autopsy study of the investigational PET amyloid imaging agent, flutemetamol.

The results revealed that both biopsy and autopsy study images had high sensitivity and specificity, and that strong concordance exists between flutemetamol PET images and Alzheimer's disease-associated beta amyloid brain pathology.

The data confirm the potential of flutemetamol as an imaging agent to detect beta amyloid plaque, a pathology associated with Alzheimer's disease in living patients.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Online foreign exchange trading company FXCM Inc (FXCM) on Wednesday announced its decision to forgive about 90% of its clients who incurred negative balances in certain jurisdictions, on January 15 as a result of the Swiss National Bank announcement on that date. FXCM will notify the applicable clients... While building a strong relationship with your customers is a key step in building any successful business, it is always hard (and often expensive) for a company to try to make amends when something goes wrong. Here is a list of 4 recent corporate apologies (most with refunds included). Social networking giant Facebook, Inc. said Wednesday after the markets closed that its fourth quarter profit rose 34% from last year, as revenue surged amid strong growth in mobile advertising. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
RELATED NEWS
Trade GE now with 
Follow RTT